%0 Journal Article
%T Evaluation of Contrast Sensitivity after Single Intravitreal Triamcinolone Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion
%A Tulin Aras Ogreden
%A Zeynep Alkin
%A Abdullah Ozkaya
%A Halil Ibrahim Demirkale
%A Irfan Perente
%A Cengiz Aras
%J ISRN Ophthalmology
%D 2013
%R 10.1155/2013/549240
%X Purpose. To evaluate visual acuity (VA), contrast sensitivity (CS), and central retinal thickness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edema secondary to branch retinal vein occlusion (BRVO). Methods. In this prospective study, a total of 21 eyes of 21 patients were included. VA, CS, and CRT were assessed at baseline and at 1, 3, and 6 months after a single IVT injection. Results. Mean age was 64.57 ¡À 8.34 years. The mean baseline VA (LogMAR) increased from 1.11 ¡À 0.63 to 0.55 ¡À 0.39 ( ), 0.60 ¡À 0.40 ( ), and 0.78 ¡À 0.39 ( ) at 1, 3, and 6 months, respectively. The mean baseline CS (log CS) at 1 meter improved from 0.66 ¡À 0.49 to 1.11 ¡À 0.32 ( ), 0.99 ¡À 0.38 ( ), and 0.72 ¡À 0.37 ( ) at 1, 3, and 6 months, respectively. The mean baseline CS (log CS) at 3 meters improved from 0.34 ¡À 0.41 to 0.74 ¡À 0.41 ( ), 0.64 ¡À 0.44 ( ), and 0.46 ¡À 0.49 ( ) at 1, 3, and 6 months, respectively. The mean baseline CRT decreased from 511 ¡À 146£¿ m to 242 ¡À 119£¿ m, 277 ¡À 131£¿ m, and 402 ¡À 166£¿ m at 1, 3, and 6 months after IVT ( for each). Conclusion. Single IVT injection improved VA and CS and reduced CRT at 1 and 3 months of treatment. VA and CS returned to baseline levels at 6 months. 1. Introduction Macular edema (ME) is the most frequent complication of branch retinal vein occlusion (BRVO) [1]. Since the Branch Vein Occlusion Study Group reported efficacy of grid laser photocoagulation, it has been accepted as the standard treatment for ME secondary to BRVO [2]. Recently, an increasing number of reports have revealed the efficacy of new treatment options for ME secondary to BRVO, such as intravitreal injection of triamcinolone acetonide (IVT), bevacizumab, ranibizumab, or aflibercept [3¨C7]. As various therapies are currently available, more detailed clinical assessment of the visual functions of these patients has become more important. Most of the previous studies evaluating the outcomes of intravitreal agents in eyes with ME secondary to BRVO assessed visual function with VA measurement [3¨C6]. VA is one of the components of functional vision and measures standard high contrast visual acuity which is not a true reflection of visual performance [8]. VA is associated with tasks requiring good resolution and adaptation to changing light conditions, whereas contrast sensitivity (CS) is associated with daily activities requiring distance judgements, night driving, and mobility [9]. Thus, CS function may give an additional information on visual performance for evaluating functional results of such treatments. Therefore, the purpose of
%U http://www.hindawi.com/journals/isrn.ophthalmology/2013/549240/